WCN26-6808 EFFECT OF SIBEPRENLIMAB ON MICROSCOPIC HEMATURIA IN ADULTS WITH IgA NEPHROPATHY: INTERIM ANALYSIS OF THE “VISIONARY” PHASE 3 TRIAL

Read full text Summarise with VIRAT
Authors: Hitoshi Suzuki, Vivekanand Jha, Manuel Praga, Michael Walsh, José Suassana, Fernando Eduardo Barbosa Nolasco, Yoram Yagil, Kenar D. Jhaveri, Raphaël Duivenvoorden, Lucia Del Vecchio, Russell T. Villanueva, Lokesh N. Shah
+3 more Jing Xia, Cecile Fajardo, Jeffrey Hafkin
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Immunoglobulin A (IgA) nephropathy is a progressive immune–mediated kidney disease characterized by deposition of Gd-IgA1–containing immune complexes in the glomerular mesangium. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and inhibits the cytokine APRIL (a proliferation-inducing ligand), a key driver of IgA nephropathy pathogenesis. The ongoing phase 3 VISIONARY trial (NCT05248646) evaluates the efficacy and safety of sibeprenlimab versus placebo in adults (aged ≥18 years) with IgA nephropathy.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106279–106279
Publication date
25 March 2026
Language
EN